← Leaderboards
Rachel Margaret Presti
Vanderbilt University Medical Center
$9,971,897
Attributed
$25,731,251
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,731,251 · 4
By mechanism
UM1$21,340,118 · 1
U01$3,065,217 · 1
U19$988,586 · 1
K08$337,330 · 1
Top collaborators
- David W Haas10 shared
- Spyros A Kalams10 shared
- Jeffrey J Atkinson5 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Jonathan E Schmitz$1,683,589
- David W Haas$38,631,058
- Spyros A Kalams$30,057,725
- Margaret Louise Salisbury$4,266,658
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseProgramsWashingtonUniversitiesInfectionClinical Trials UnitHiv InfectionsProtocols DocumentationHiv-1IncidencePrevalenceMolecularCellsImmunologyUnited StatesSiteTuberculosisFundingAreaEpidemiologyPlayClinical Research SiteNational Institute Of Allergy And Infectious DiseasePandemic Disease
Grant awards (20)
Vanderbilt HIV Clinical Trials Unit (CTU)$2,720,209
UM1 · FY2025 · AI
Core B - Clinical Core$533,133
U19 · FY2025 · AI · contact PI
Vanderbilt HIV Clinical Trials Unit (CTU)$2,649,501
UM1 · FY2024 · AI
Core B - Clinical Core$455,453
U19 · FY2024 · AI · contact PI
Vanderbilt HIV Clinical Trials Unit (CTU)$2,106,727
UM1 · FY2023 · AI
Vanderbilt HIV Clinical Trials Unit (CTU)$2,679,601
UM1 · FY2022 · AI
Vanderbilt HIV Clinical Trials Unit (CTU)$2,577,612
UM1 · FY2021 · AI
Vanderbilt HIV Clinical Trials Unit$2,487,433
UM1 · FY2020 · AI
Vanderbilt CTU SARS-CoV-2 Supplement$558,406
UM1 · FY2020 · AI
Vanderbilt HIV Clinical Trials Unit$2,941,559
UM1 · FY2019 · AI
Vanderbilt HIV Clinical Trials Unit$1,615,311
UM1 · FY2018 · AI
Vanderbilt HIV Clinical Trials Unit$1,003,759
UM1 · FY2017 · AI
MOLECULAR MECHANISMS OF CHRONIC AIRWAY AND ALVEOLAR DISEASE IN HIV$585,644
U01 · FY2017 · HL
MOLECULAR MECHANISMS OF CHRONIC AIRWAY AND ALVEOLAR DISEASE IN HIV$622,967
U01 · FY2016 · HL
MOLECULAR MECHANISMS OF CHRONIC AIRWAY AND ALVEOLAR DISEASE IN HIV$621,875
U01 · FY2015 · HL
MOLECULAR MECHANISMS OF CHRONIC AIRWAY AND ALVEOLAR DISEASE IN HIV$636,058
U01 · FY2014 · HL
MOLECULAR MECHANISMS OF CHRONIC AIRWAY AND ALVEOLAR DISEASE IN HIV$598,673
U01 · FY2013 · HL
The Role of NKG2D/DAP10 in Toxoplasma gondii Infection$115,190
K08 · FY2010 · AI · contact PI
The Role of NKG2D/DAP10 in Toxoplasma gondii Infection$112,414
K08 · FY2009 · AI · contact PI
The Role of NKG2D/DAP10 in Toxoplasma gondii Infection$109,726
K08 · FY2008 · AI · contact PI